The effect of esketamine on the demand for vasoactive drugs in patients with cardiac valve replacement

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200056840

Enrollment

Unknown

Registered

2022-02-19

Start date

2022-02-10

Completion date

Unknown

Last updated

2023-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Group S:Propofol plus esketamine for continuous analgesia and sedation

Group A:Propofol plus remifentanil for continuous analgesia and sedation

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged >18 years and <65 years; 2. Patients undergoing elective open-heart valve surgery and requiring ventilator support in the ICU for at least 1 day after surgery; 3. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Preoperative cognitive dysfunction or other mental diseases; 2. After cardiac resuscitation; 3. Hypertensive crisis (SBP >200 mmHg/DBP>110mmHg); 4. Unstable angina pectoris or myocardial infarction occurred within six months; 5. Acute brain injury; 6. Patients with increased intracranial pressure; 7. Severe liver and kidney diseases; 8. Pregnant patients.

Design outcomes

Primary

Measure	Time frame
The dose of norepinephrine required to achieve a mean arterial pressure of 65 to 75mmHg when both groups achieved an RASS sedation score of 2;	—

Secondary

Measure	Time frame
The total amount of propofol, remifentanil, and esketamine;The number of tachycardia, hypertension and hypotension;The incidence of delirium within 3 days after surgery (CAM-ICU);Postoperative inflammatory reaction;	—

Countries

China

Contacts

Public ContactZhou Quanhong

The Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

zhouanny@hotmail.com+86 13761441463

Outcome results